ImmunisLogoWImmunisLogocropped-immunislogo.pngcropped-immunislogo.png
  • Home
  • About
  • Technology
  • Clinical Trials
  • News
  • Media
  • Contact
✕
  • Home
  • Immunis Featured in Lifespan.io
Immunis Announces First-in-Human Injection of Secretome Product for Age-Related Muscle Atrophy
Immunis Chairman Dr. Hans Keirstead to Present at the 2023 Biotech Showcase
January 6, 2023
IRVINE, Calif. — January 6, 2023 —

Immunis Inc.‘s press release announcing the first-in-human injection of STEM was highlighted by Lifespan.io, an online news source for breakthrough technologies and scientific discoveries in aging and longevity. The article is entitled “Immunis Begins Clinical Trial of Stem Cell Secretome.” The high-level, scientific content for Lifespan.io is supported by The Lifespan Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization promoting fundamental research on aging and age-related diseases, as well as educating the public on the possibility of preventing age-related diseases.

###

Share

Recent News

  • May 19, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at the BIO International Convention

  • May 17, 2023

    Immunis Chairman Dr. Hans Keirstead to Present at the 5th Age-Related Disease Therapeutics Summit

  • May 8, 2023

    Immunis Appoints Mark Cabato as Chief Business Officer

Navigation

  • Home
  • About
  • Technology
  • Clinical Trials
  • News
  • Media
  • Contact

Contact info

Immunis, Inc.
Irvine, California


contact@immunisbiomedical.com

© 2023 Immunis, Inc. | All Rights Reserved